SEPTIC SHOCK Clinical Trial
— EARTH-ICUOfficial title:
Effect of Early Physical Activity on Skeletal Muscle Signaling Pathways Controlling Protein Turnover in Patients With Sepsis.
It is clearly shown that patients in the Intensive care Unit (ICU) with severe sepsis or
multi organic failure are very susceptible to develop neuromuscular complications. That can
be attributed to a hyper catabolic state, general inflammation and immobilization. This can
leads a significant muscle wasting, polyneuropathy and/or myopathy. These alterations have
been defined with the term Intensive Care Acquired Weakness (ICUAW) and can leads important
functional squeals and impaired quality of life for months, years and in some cases
irreversibly.
To overcome these complications, early activation by physiotherapy becomes an important
tool. This type of treatment has been show to be feasible, safe and improves the functional
capacity of patients. In addition to a reduction in the duration of ICU and hospital stay
and improved quality of life for patients.
The objective of this study is to demonstrate that the early and active physical activity in
patients with severe sepsis can limit the loss of muscle mass and complications related to
this type of damage.
Procedures: Patients or relatives will be asked to participate in the study. If a positive
response is done, patients will be randomized in an intervention or control group.
A baseline evaluation will be performed during the first day of study admission. That
includes a physical exploration, electrophysiological studies, skeletal muscle
histological/biochemical evaluations and monitoring of blood biomarkers and others clinical
outcomes will be registered.
Intervention will be divided in a morning and afternoon times, patient will be positioned in
chair or bed and mobilized by physiotherapist. As usual, all patients will be attaining
manual mobilization for 20 minutes twice a day. Only for intervention group, additional
cycle-ergometer exercise will be performed for 30 minutes at better performance achieved and
tolerated for patient. All vitals parameters will be strictly controlled before, during and
after intervention.
The same baseline evaluation will be repeated after day 7 and clinical outcomes will be
registered until ICU discharge.
Status | Terminated |
Enrollment | 29 |
Est. completion date | November 2015 |
Est. primary completion date | June 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 85 Years |
Eligibility |
Inclusion Criteria: - Hemodynamically stable patients. - Admitted to ICU for sepsis or MOF (multiple organ failure) or who developing during their ICU stay within the first 24 hours of the ICU admission. - With an expected ICU stay of at least 7 days. Exclusion Criteria: - Patients without approved consent. - Patients with a known neuromuscular disorder before ICU admission. - Moribund patients. - Severe metabolic/hemodynamic instability despite pharmacological support. - Having conditions that impair evaluation techniques or intervention methods. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
Belgium | Cliniques universitaires Saint-Luc- Université Catholique de Louvain (StLuc) | Brussels |
Lead Sponsor | Collaborator |
---|---|
Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in activation of skeletal muscle synthetic and catabolic pathways. | Within the first 7 days (plus or minus 1 days) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03649633 -
Vitamin C, Steroids, and Thiamine, and Cerebral Autoregulation and Functional Outcome in Septic Shock
|
Phase 1/Phase 2 | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Completed |
NCT05629780 -
Temporal Changes of Lactate in CLASSIC Patients
|
N/A | |
Recruiting |
NCT04796636 -
High-dose Intravenous Vitamin C in Patients With Septic Shock
|
Phase 1 | |
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Recruiting |
NCT05066256 -
LV Diastolic Function vs IVC Diameter Variation as Predictor of Fluid Responsiveness in Shock
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 | |
Not yet recruiting |
NCT04516395 -
Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae
|
N/A | |
Recruiting |
NCT02899143 -
Short-course Antimicrobial Therapy in Sepsis
|
Phase 2 | |
Recruiting |
NCT02580240 -
Administration of Hydrocortisone for the Treatment of Septic Shock
|
N/A | |
Recruiting |
NCT02676427 -
Fluid Responsiveness in Septic Shock Evaluated by Caval Ultrasound Doppler Examination
|
||
Recruiting |
NCT02565251 -
Volemic Resuscitation in Sepsis and Septic Shock
|
N/A | |
Terminated |
NCT02335723 -
ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber
|
N/A | |
Not yet recruiting |
NCT02547467 -
TOADS Study: TO Assess Death From Septic Shock.
|
N/A | |
Completed |
NCT02638545 -
Hemodynamic Effects of Dexmedetomidine in Septic Shock
|
Phase 3 | |
Completed |
NCT02204852 -
Co-administration of Iloprost and Eptifibatide in Septic Shock Patients
|
Phase 2 | |
Completed |
NCT02079402 -
Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care
|
Phase 4 |